BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear. METHODS: Whole-exome sequencing identified a novel DSC2 sequence variation causing autosomal recessive ARVC in a Chinese family with consanguineous marriage. Mouse models with Dsc2 sequence variation knock-in and constitutive knock-out were generated and analyzed using echocardiography and histology. Transcriptomic and biochemical analyses were conducted to explore ARVC mechanisms. Dsc2 mRNA delivered by intracardiac or transcoronary injection was assessed as a treatment for ARVC in Dsc2 knock-out mice. In addition, effects of Dsc2 mRNA were examined in a transverse aortic constriction mouse model with noninherited right ventricular systolic dysfunction. RESULTS: Dsc2 -deficient mice exhibited right ventricular dilation and dysfunction, mimicking human disease. Transcriptomic analysis identified Myl7 as the most downregulated gene in the right ventricles of Dsc2 -deficient mice, and its restoration by adeno-associated virus 9 rescued heart function. Dsc2 mRNA delivery, with or without lipid nanoparticle encapsulation, normalized heart size and function in Dsc2 -deficient mice. Reduced DSC2 and MLC2a expression was also noted in patients with noninherited dilated cardiomyopathy and in mice with transverse aortic constriction. A single dose of mRNA provided therapeutic effects lasting 2 to 3 months before declining. CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by DSC2 loss of function, supported by human and mouse data. Loss of Myl7 contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. Dsc2 mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.
Background: Serotonin, as an important neurotransmitter and signaling molecule, can affect thoracic aortic aneurysm (TAA) by regulating vascular cell proliferation, angiogenesis, and immune status. This research aimed to conduct a comprehensive analysis to pinpoint serotonin-related biomarkers in TAA and to elucidate their potential molecular mechanisms. Methods: Biomarkers were selected and validated through differential expression analysis, weighted gene co-expression network analysis (WGCNA), machine learning algorithms, and expression verification. Moreover, the constructed nomogram, enrichment analysis, immune infiltration analysis, and compound prediction validated the regulatory roles of the biomarkers in TAA. The single-cell dataset was analyzed to determine key cells and perform pseudo-time analysis. Simulated knockout of biomarkers was performed to determine their underlying functions and related pathways. Finally, reverse transcription quantitative PCR (RT-qPCR) was employed to confirm the expression levels of the biomarkers. Results: Overall, two biomarkers (CD300A and CLU) were determined to be associated with serotonin in TAA. The nomogram showed good performance in predicting TAA risk. These biomarkers were significantly enriched in the hematopoietic cell lineage and natural killer (NK) cell mediated cytotoxicity. Biomarker expression was significantly correlated with the infiltration proportions of M2 macrophages and neutrophils. The biomarkers were stably bound to tetrachlorodibenzodioxin and bisphenol A. Moreover, pseudo-time analysis demonstrated a notable correlation between biomarker expression and the differentiation status of monocytes/macrophages/dendritic cells (MonoMac/DC). Genes perturbed by knockout were enriched in the pyrimidine metabolism and RIG-I-like receptor signaling pathway. Finally, RT-qPCR validated that CLU was downregulated and CD300A was upregulated in the TAA group. Conclusions: Biomarkers (CD300A and CLU) associated with serotonin in TAA were identified, with their expression trends validated by RT-qPCR. This work provides novel bioinformatic insights, and direct functional experiments are required to support future therapeutic development for TAA.